Chris Ryan

Chris Ryan joined OncLive in November 2021 as a senior editor and became the website's managing editor in October 2023. Before arriving at MJH Life Sciences, he spent nearly a decade covering professional and high school sports—including the New Jersey Devils and the NHL from 2016 to 2021—for The Star-Ledger and NJ.com. Email: chryan@onclive.com

Articles

Neoadjuvant Atezolizumab Plus Chemotherapy Numerically Improves Survival in Early TNBC

May 12th 2023

The addition of atezolizumab to neoadjuvant chemotherapy generated numerical improvements in event-free survival, disease-free survival, and overall survival compared with chemotherapy plus placebo in patients with early-stage triple-negative breast cancer.

FDA Issues Complete Response Letter to BLA for N-803 in BCG-unresponsive NMIBC in Situ

May 11th 2023

The FDA has issued a complete response letter regarding the biologics license application for N-803 in combination with Bacillus Calmette-Guérin (BCG) for the treatment of patients with BCG-unresponsive non–muscle-invasive bladder cancer with carcinoma in situ with or without Ta or T1 disease.

Ivosidenib Wins European Approval for IDH1-mutated AML and Cholangiocarcinoma

May 10th 2023

The European Commission has approved ivosidenib tablets in combination with azacitidine for the treatment of adult patients with newly diagnosed acute myeloid leukemia with an IDH1 R132 mutation who are not eligible to receive standard induction chemotherapy, and as monotherapy for the treatment of adult patients with locally advanced or metastatic cholangiocarcinoma with an IDH1 R132 mutation who received at least 1 prior line of systemic therapy.

FDA Grants Orphan Drug Status to RAD 301 for Imaging of Pancreatic Ductal Adenocarcinoma

May 10th 2023

The FDA has granted an orphan drug designation to RAD 301 for the imaging of patients with pancreatic ductal adenocarcinoma.

FDA Grants Fast Track Designation to ACR-368 in Platinum-resistant Ovarian Cancer and Endometrial Cancer

May 9th 2023

The FDA has granted fast track designations to ACR-368 monotherapy for the treatment of patients with platinum-resistant ovarian cancer and endometrial cancer who are positive for predicted sensitivity to the agent using Acrivon Therapeutics’ OncoSignature® test.

China Approves Zanubrutinib in Previously Untreated CLL/SLL and Waldenström Macroglobulinemia

May 8th 2023

China’s National Medical Products Administration has approved 2 supplemental new drug applications of zanubrutinib for use in treatment-naïve adult patients with chronic lymphocytic leukemia or small lymphocytic lymphoma and Waldenström macroglobulinemia.

Sintilimab Plus Chemo With or Without IBI305 Provides PFS Benefit in EGFR TKI–Pretreated EGFR+ NSCLC

May 8th 2023

The combination of sintilimab and chemotherapy with or without the bevacizumab biosimilar IBI305 produced a statistically significant and clinically meaningful improvement in progression-free survival vs chemotherapy alone in patients with EGFR-mutated, nonsquamous non–small cell lung cancer who progressed after treatment with an EGFR TKI.

FDA Grants 501K Clearance to Bladder EpiCheck for Surveillance in NMIBC

May 5th 2023

The FDA has granted 510K clearance to Bladder EpiCheck for use as a noninvasive method for surveillance of tumor recurrence in previously diagnosed patients with non–muscle invasive bladder cancer, in conjunction with cystoscopy.

FDA Approves Companion Diagnostic for Mobocertinib in Advanced NSCLC With EGFR Exon 20 Insertion Mutations

May 4th 2023

The FDA has approved FoundationOne® Liquid CDx as a companion diagnostic for mobocertinib in patients with locally advanced or metastatic non–small cell lung cancer harboring EGFR exon 20 insertion mutations.

Liso-cel Earns European Approval for Relapsed/Refractory LBCL After 1 Prior Therapy

May 3rd 2023

The European Commission has approved lisocabtagene maraleucel for the treatment of adult patients with diffuse large B-cell lymphoma, high-grade B-cell lymphoma, primary mediastinal large B-cell lymphoma, and follicular lymphoma grade 3B who relapsed within 12 months from completion of, or are refractory to, first-line chemoimmunotherapy.

FDA Grants Fast Track Designation to ERAS-801 in EGFR-altered Glioblastoma

May 2nd 2023

The FDA has granted a fast track designation to ERAS-801 for the treatment of adult patients with glioblastoma harboring EGFR gene alterations.

First-line Cemiplimab Plus Chemo Wins Approval in Canada for Advanced NSCLC

May 2nd 2023

Health Canada has approved the combination of cemiplimab and platinum-based chemotherapy for the first-line treatment of patients with locally advanced or metastatic non–small cell lung cancer without EGFR, ALK, or ROS1 aberrations who are not candidates for definitive chemoradiation.

FDA Grants Priority Review to Luspatercept for First-line Treatment of Anemia in Lower-risk MDS

May 1st 2023

The FDA has granted a priority review to the supplemental biologics license application seeking to expand the current indication of luspatercept to include treatment of anemia in patients with very low- to intermediate-risk myelodysplastic syndrome who have not previously received erythropoiesis-stimulating agents and who may require red blood cell transfusions.

Darolutamide Associated With Lower Rates of Treatment Discontinuation and Disease Progression in nmCRPC

April 29th 2023

Treatment with darolutamide was associated with lower rates of discontinuation and progression to metastatic disease compared with enzalutamide and apalutamide in patients with nonmetastatic castration-resistant prostate cancer.

AUA Releases Clinical Practice Guideline for Nonmetastatic Upper Tract Urothelial Carcinoma

April 27th 2023

The American Urological Association and Society of Urologic Oncology have released a clinical practice guideline for the diagnosis and management of patients with nonmetastatic upper tract urothelial carcinoma.

ASTRO/ESTRO Release Clinical Guideline for Local Therapy in Oligometastatic NSCLC

April 26th 2023

The American Society for Radiation Oncology and European Society for Radiotherapy & Oncology have released the first clinical guideline on the use of definitive local therapy, including radiation and surgery, for the treatment of patients with oligometastatic non–small cell lung cancer.

FDA Grants Fast Track Designation to 177Lu-PNT2002 for mCRPC

April 25th 2023

The FDA has granted a fast track designation to 177Lu-PNT2002 for the treatment of patients with metastatic castration-resistant prostate cancer.

Tislelizumab Plus Chemotherapy Meets OS End Point in Advanced Gastric/GEJ Adenocarcinoma

April 21st 2023

The combination of tislelizumab plus chemotherapy elicited a statistically significant and clinically meaningful improvement in overall survival compared with chemotherapy plus placebo in patients with advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma.

FDA Extends Review for Quizartinib in Newly Diagnosed FLT3-ITD+ AML

April 21st 2023

The FDA has extended the review period for a new drug application for quizartinib in combination with standard cytarabine and anthracycline induction and standard cytarabine consolidation chemotherapy, and as continuation monotherapy following consolidation, for the treatment of newly diagnosed adult patients with FLT3-ITD–positive acute myeloid leukemia.

VB10.16 Plus Atezolizumab Generates Positive Survival Data in PD-L1+ Advanced Cervical Cancer

April 20th 2023

The combination of the potentially first-in-class off-the-shelf therapeutic cancer vaccine candidate VB10.16 and atezolizumab elicited a median overall survival greater than 25 months in patients with PD-L1–positive, human papillomavirus 16–positive advanced cervical cancer.